Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia

Schreiner, Andreas; Aadamsoo, Kaire; Altamura, A.; Franco, Manuel; Gorwood, Philip; Neznanov, Nikolaj; SCHRONEN, Juan; Ucok, Vehbi; ZINK, Mathias; JANIK, Adam; CHERUBIN, Pierre; LAHAYE, Marjolein; HARGARTER, Ludger

doi:10.1016/j.schres.2015.08.015

Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia

Schreiner A., Aadamsoo K., Altamura A. C., Franco M., Gorwood P., Neznanov N. G., ...Daha Fazla

SCHIZOPHRENIA RESEARCH, cilt.169, ss.393-399, 2015 (SCI-Expanded, SSCI, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 169
Basım Tarihi: 2015
Doi Numarası: 10.1016/j.schres.2015.08.015
Dergi Adı: SCHIZOPHRENIA RESEARCH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus
Sayfa Sayıları: ss.393-399
İstanbul Üniversitesi Adresli: Evet

Özet

Objective: Relapse and acute exacerbation are common in schizophrenia and may impact treatment response and outcome. Evidence is conflicting in respect to superiority of long-acting injectable antipsychotic therapies versus oral antipsychotics in relapse prevention. This randomized controlled study assessed the efficacy of paliperidone palmitate versus oral antipsychotics for relapse prevention.